pSivida Corp

Investor Relations Home

pSivida develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. We have developed three of the four products approved in either the U.S. or the EU for sustained release delivery of drug to treat chronic back-of-the-eye diseases utilizing multiple generations of our Durasert technology system.

Our lead development product, ILUVIEN® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology.The US Food and Drug Administration (FDA) approved ILUVIEN for the treatment of diabetic macular edema (DME) for patients treated with a course of corticosteroids and did not have a significant rise in intraocular pressure (IOP). ILUVIEN is marketed in the U.K., Germany and Portugal and has or is pending marketing autorization in 14 other EU countries.
 

pSivida’s other two FDA-approved products, Retisert® and Vitrasert®, licensed to Bausch & Lomb, Inc., are implants utilizing earlier generations of our Durasert technology system that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

View all »   RSS

Recent Releases

Feb 1, 2016
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information

Jan 28, 2016
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9

View all »

Events & Presentations

Feb 8, 2016 at 4:30 PM ET
Q2 2016 pSivida Corp. Earnings Conference Call

Feb 9, 2016 at 11:00 AM ET
18th Annual Bio CEO & Investor Conference


IR Contacts

Beverly Jedynak
President
Martin E. Janis & Company
Phone: 312-943-1123
bjedynak@janispr.com

Transfer Agent:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940 USA
Phone: 781-575-2879
Fax: 781-575-3605

 
pSivida